BioLife Solutions, Inc. reported $103M of revenue over the trailing twelve months, +25% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $103M (to Q2 2026). Net income: $58M, trailing twelve months to Q2 2026. Free cash flow: $8.6M, trailing twelve months to Q2 2026. Operating margin: 3.2%, trailing twelve months to Q2 2026.

BLFSBioLife Solutions, Inc.

Healthcare

$38.58+50% 1Y

$38.58

$18.1552 weeks$39.24

BLFS as reported

BioLife Solutions, Inc. reported $103M of revenue over the trailing twelve months, +25% on the year before. 10 reported series are charted on this page, each one as filed.

$103M

Revenue, trailing twelve months · to Q2 2026 · +25% against the twelve months before

Net income: $58M
Net income · −1148% year on year · trailing twelve months to Q2 2026
Free cash flow: $8.6M
Free cash flow · −114% year on year · trailing twelve months to Q2 2026
Operating margin: 3.2%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for BLFS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$103M	+25%	Q2 2026
Net income	$58M	−1148%	Q2 2026
EPS	$1.17	−1164%	Q2 2026
Gross margin	59%	n/a	Q3 2020 · 23 quarters behind
Operating margin	3.2%	n/a	Q2 2026
Net margin	56%	n/a	Q2 2026
ROE	2.7%	n/a	Q2 2026
ROA	2.6%	n/a	Q2 2026
ROIC	−3.0%	n/a	Q2 2026
Free cash flow	$8.6M	−114%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.